<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">VACCINIA IMMUNE GLOBULIN (VIG-IV)</span><br/>(vac-cin'i-a)<br/><span class="topboxtradename">Vaccinia Immune Globulin (VIG, VIG-IV)<br/></span><b>Classifications:</b> <span class="classification">biologic response modifier</span>; <span class="classification">immunoglobulin</span><br/><b>Prototype: </b>Immune Globulin Intravenous<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Vaccinia immune globulin, VIG (VIG-IV) is an intravenous sterile solution of purified human immunoglobulin G (IgG) with trace
         amounts of IgA and IgM. It is derived from adult human plasma collected from donors who received booster immunizations with
         the smallpox vaccine. VIG (VIG-IV) contains high titers of antivaccinia antibodies.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>VIG is effective in the treatment of smallpox vaccine adverse reactions secondary to continued vaccinia virus replication
         after vaccination.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Prevention of serious complications of smallpox vaccine; treatment of progressive vaccinia; severe generalized vaccinia; eczema
         vaccinatum; vaccinia infection in patients with skin conditions (e.g., burns, impetigo, varicella-zoster, poison ivy, or eczematous
         skin lesions); treatment or modification of aberrant infections induced by vaccinia virus.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Predisposition to acute renal failure (i.e., preexisting renal insufficiency, diabetes mellitus, volume depletion, sepsis,
         patients &gt;65 y); postvaccinal encephalitis; lactation. 
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Concurrent administration of known nephrotoxic drugs; pregnancy (category C).</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Vaccinia</span><br/><span class="rdage">Adults:</span> <span class="rdroute">IV</span> 100500 mg/kg<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Dose reduction is required. Maximum dose: 400 mg/kg.<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> No dilution required. Use solution as supplied.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Begin infusion within 6 h of entering the vial. Complete infusion within 12 h of entering the vial. Use in-line filter (0.22
                  microns), infusion pump, and dedicated IV line [may infuse into a preexisting catheter if it contains NS, D2.5W, D5W, D10W,
                  or D20W (or any combination of these)]. Infuse at 1.0 mL/kg/h the first 30 min, increase to 2.0 mL/kg/h the next 30 min, and
                  then increase to 3.0 mL/kg/h until infused.  
               </p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Injection site reaction. <span class="typehead">CNS:</span> Dizziness, <span class="speceff-common">headache</span>. <span class="typehead">GI:</span> Abdominal pain, nausea, vomiting. <span class="typehead">Musculoskeletal:</span> Arthralgia, back pain. <span class="typehead">Respiratory:</span> Upper respiratory infection. <span class="typehead">Skin:</span> Erythema, flushing. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May interfere with the immune response to live virus <span class="classification">vaccines</span>. Vaccination with live virus <span class="classification">vaccines</span> should be deferred until approximately 6 mo after administration of VIG-IV. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Half-Life:</span> 22 d. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor vital signs continuously during infusion, especially after infusion rate changes.</li>
<li>Slow infusion rate for any of the following: flushing, chills, muscle cramps, back pain, fever, nausea, vomiting, arthralgia,
            and wheezing.
         </li>
<li>DC infusion, institute supportive measures, and notify physician for any of the following: increase in heart rate, increase
            in respiratory rate, shortness of breath, rales or other signs of anaphylaxis.
         </li>
<li>Have loop diuretic available for management of fluid overload.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Promptly report any discomfort that develops while drug is being infused.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>